Accrued expenses and other current liabilities

6 Months Ended

Jun. 30, 2026

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

5	Accrued expenses and other current liabilities

Accrued expenses and other current liabilities include the following items:


		June 30,		December 31,
		2026		2025

		(in thousands)
Accruals for goods received from and services provided by vendors, not yet billed		$	24,684	$	20,490
Personnel-related accruals and liabilities (As of June 30, 2026, $7.2 million (December 31, 2025: $0.0 million) related to cash proceeds from employees' stock option exercises)			16,654		9,941
Liability owed to the Purchaser pursuant to the Royalty Financing Agreement (refer to Note 7, "Royalty Financing Agreement")			5,778		5,523
Current portion of firm purchase commitment liability (including Genezen CSA termination payment)			3,808		5,102
Other current liabilities			209		236
Total		$	51,133	$	41,292

In April 2026, the Company entered into an agreement to terminate the commercial supply agreement (the “Genezen CSA”) with Genezen MA, Inc. (together with Genezen Holdings Inc., “Genezen”). Pursuant to the termination agreement, our obligation to supply HEMGENIX^® and any minimum purchase commitments under the Genezen CSA terminate once contractually specified batches have been supplied. In connection with the termination, the Company wrote down the remaining carrying value of the intangible asset for the favorable supply terms under the Genezen CSA. The net effect of these items was recorded in Other expense, and did not have a material impact on the Company’s results of operations for the three and six months ended June 30, 2026.